{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:11:56Z","timestamp":1793661116736,"version":"4.5.1"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tjpad.2025.100094","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T15:46:21Z","timestamp":1740498381000},"page":"100094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-4289","authenticated-orcid":false,"given":"Nicolas","family":"Villain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-227X","authenticated-orcid":false,"given":"Vincent","family":"Planche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4622-2413","authenticated-orcid":false,"given":"Matthieu","family":"Lilamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Soto-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Mollion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Bombois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Delrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1474-4422(23)00449-0","article-title":"Dementia research in 2023: the year of anti-amyloid immunotherapy","volume":"23","author":"Delrieu","year":"2024","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100094_bib0003","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.neurol.2022.08.002","article-title":"High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France","volume":"178","author":"Villain","year":"2022","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib0004","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"19","key":"10.1016\/j.tjpad.2025.100094_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0006","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib0007","doi-asserted-by":"crossref","first-page":"165","DOI":"10.12779\/dnd.2024.23.4.165","article-title":"Lecanemab: appropriate use recommendations by Korean Dementia Association","volume":"23","author":"Park","year":"2024","journal-title":"Dement Neurocognitive Disord"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib0008","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100094_bib0009","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamaneurol.2023.0815","article-title":"Advocating for demonstration of disease modification-have we been approaching clinical trials in early Alzheimer disease incorrectly?","volume":"80","author":"Planche","year":"2023","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jnnp-2023-331941","article-title":"Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials","volume":"95","author":"Goldberg","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0011","doi-asserted-by":"crossref","first-page":"fcad175","DOI":"10.1093\/braincomms\/fcad175","article-title":"Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease","volume":"5","author":"Liu","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.tjpad.2025.100094_bib0087","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-section-48-undesirable-effects_en.pdf."},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0012","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0013","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1016\/j.tjpad.2025.100094_bib0016","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1016\/j.tjpad.2025.100094_bib110","first-page":"209","article-title":"Standardisation et \u00e9talonnage fran\u00e7ais du Mini Mental State (MMS) version GRECO","author":"Kalafat","year":"2003","journal-title":"Revue de Neuropsychologie"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib111","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/23279095.2021.1952588","article-title":"Influence of education level on MMSE and MoCA scores of elderly inpatients","volume":"30","author":"Wu","year":"2023","journal-title":"Appl Neuropsychol Adult"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib112","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/09084282.2011.643962","article-title":"Is the Folstein\u2019s Mini-Mental test an aphasia test?","volume":"19","author":"Vigliecca","year":"2012","journal-title":"Appl Neuropsychol Adult"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib113","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"The Gerontologist"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0017","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.tjpad.2025.100094_bib114","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000. (page 157-158). In."},{"issue":"11","key":"10.1016\/j.tjpad.2025.100094_bib0018","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nrneurol.2014.181","article-title":"Classifying neurocognitive disorders: the DSM-5 approach","volume":"10","author":"Sachdev","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae183","article-title":"Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome","volume":"6","author":"Corriveau-Lecavalier","year":"2024","journal-title":"Brain Commun"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0020","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.25333","article-title":"Prevalence of amyloid-\u03b2 pathology in distinct variants of primary progressive aphasia","volume":"84","author":"Bergeron","year":"2018","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100094_bib0021","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1474-4422(23)00414-3","article-title":"Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis","volume":"23","author":"Chapleau","year":"2024","journal-title":"Lancet Neurol"},{"issue":"Pt 7","key":"10.1016\/j.tjpad.2025.100094_bib0022","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/brain\/awr130","article-title":"Similar amyloid-\u03b2 burden in posterior cortical atrophy and Alzheimer's disease","volume":"134","author":"de Souza","year":"2011","journal-title":"Brain J Neurol"},{"issue":"Pt 9","key":"10.1016\/j.tjpad.2025.100094_bib0023","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1093\/brain\/awv191","article-title":"The behavioural\/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features","volume":"138","author":"Ossenkoppele","year":"2015","journal-title":"Brain J Neurol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100094_bib0024","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1007\/s00415-015-7904-3","article-title":"Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis","volume":"262","author":"Paterson","year":"2015","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100094_bib0025","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.neurobiolaging.2015.04.011","article-title":"Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease","volume":"36","author":"Ossenkoppele","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100094_bib0026","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/brain\/awab099","article-title":"Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease","volume":"144","author":"Spina","year":"2021","journal-title":"Brain J Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100094_bib0027","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0028","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","article-title":"Four distinct trajectories of tau deposition identified in Alzheimer's disease","volume":"27","author":"Vogel","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100094_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007967","article-title":"Cognitive heterogeneity in probable Alzheimer disease: clinical and neuropathologic features","volume":"93","author":"Qiu","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/alz.12231","article-title":"Clinical relevance of brain atrophy subtypes categorization in memory clinics","volume":"17","author":"Planche","year":"2021","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100094_bib0031","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","article-title":"Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration","volume":"98","author":"Mattsson-Carlgren","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0032","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ana.25893","article-title":"Sensitivity-specificity of tau and amyloid \u03b2 positron emission tomography in frontotemporal lobar degeneration","volume":"88","author":"Ghirelli","year":"2020","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100094_bib0033","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/brain\/awx254","article-title":"Clinicopathological correlations in behavioural variant frontotemporal dementia","volume":"140","author":"Perry","year":"2017","journal-title":"Brain J Neurol"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100094_bib0034","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/jnnp-2021-328586","article-title":"Neuropathology and emerging biomarkers in corticobasal syndrome","volume":"93","author":"Koga","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100094_bib0035","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0036","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa068","article-title":"Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes","volume":"2","author":"Townley","year":"2020","journal-title":"Brain Commun"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100094_bib0037","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain J Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0038","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/brain\/awac158","article-title":"Biomarker A+T-: is this Alzheimer's disease or not? A combined CSF and pathology study","volume":"146","author":"Vromen","year":"2023","journal-title":"Brain J Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0039","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100094_bib0040","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"15","key":"10.1016\/j.tjpad.2025.100094_bib0041","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100094_bib0042","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100094_bib0043","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0081","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100094_bib0085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.neurol.2022.06.012","article-title":"High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: meta-analysis and review of efficacy and safety data, and medico-economical aspects","volume":"178","author":"Villain","year":"2022","journal-title":"Rev Neurol (Paris)"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0044","first-page":"38","article-title":"Rate of early onset Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Zhu","year":"2015","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1976.00500040001001","article-title":"Editorial: the prevalence and malignancy of Alzheimer disease. A major killer","volume":"33","author":"Katzman","year":"1976","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0046","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100094_bib0047","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2025.100094_bib0052","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-017-0294-2","article-title":"Early- versus late-onset Alzheimer\u2019s disease in clinical practice: cognitive and global outcomes over 3 years","volume":"9","author":"Wattmo","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100094_bib0049","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neurobiolaging.2017.01.024","article-title":"Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease","volume":"53","author":"Cho","year":"2017","journal-title":"Neurobiol Aging"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100094_bib0048","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/alz.12350","article-title":"The Longitudinal early-onset Alzheimer's Disease Study (LEADS): framework and methodology","volume":"17","author":"Apostolova","year":"2021","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0050","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer's disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2025.100094_bib0051","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neurobiolaging.2017.08.009","article-title":"18F-FDG PET hypometabolism patterns reflect clinical heterogeneity in sporadic forms of early-onset Alzheimer's disease","volume":"59","author":"Vanhoutte","year":"2017","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0053","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneurol.2011.221","article-title":"Autosomal recessive causes likely in early-onset Alzheimer disease","volume":"69","author":"Wingo","year":"2012","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0054","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.26511","article-title":"Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of Gantenerumab and Solanezumab: lessons from a trial in dominantly inherited Alzheimer disease","volume":"92","author":"Joseph-Mathurin","year":"2022","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100094_bib0082","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100094_bib0056","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0057","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/STROKEAHA.110.607184","article-title":"Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study","volume":"42","author":"Poels","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.tjpad.2025.100094_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101336","article-title":"Malnutrition is positively associated with cognitive decline in centenarians and oldest-old adults: a cross-sectional study","volume":"47","author":"Feng","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0059","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/gerona\/glz244","article-title":"NILVAD Study Group. Is ongoing anticholinergic burden associated with greater cognitive decline and dementia severity in mild to moderate Alzheimer's Disease?","volume":"75","author":"Dyer","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.tjpad.2025.100094_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104336","article-title":"Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology","volume":"86","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100094_bib0061","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/jgs.17206","article-title":"Sarcopenia is associated with incident Alzheimer's dementia, mild cognitive impairment, and cognitive decline","volume":"69","author":"Beeri","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100094_bib0062","first-page":"191","article-title":"Impact of frailty on outcomes of first-line pembrolizumab monotherapy in a real-world population with advanced non-small cell lung cancer","volume":"12","author":"Jim\u00e9nez Gal\u00e1n","year":"2023","journal-title":"Biology (Basel)"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0063","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3322\/caac.21406","article-title":"Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology","volume":"67","author":"Ethun","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100094_bib0064","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(18)30371-5","article-title":"Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project","volume":"18","author":"Wallace","year":"2019","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100094_bib0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12603-012-0084-2","article-title":"A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans","volume":"16","author":"Morley","year":"2012","journal-title":"J Nutr Health Aging"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0066","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100094_bib0067","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1474-4422(23)00131-X","article-title":"Neuroimaging standards for research into small vessel disease-advances since 2013","volume":"22","author":"Duering","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100094_bib0068","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3174\/ajnr.A1355","article-title":"MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength","volume":"30","author":"Nandigam","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.tjpad.2025.100094_bib0069","article-title":"SWI versus GRE-T2*: assessing cortical superficial siderosis in advanced cerebral amyloid angiopathy","author":"Assis Lopes","year":"2023","journal-title":"Rev Neurol (Paris)"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0070","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.crad.2010.01.004","article-title":"Choice of echo time on GRE T2*-weighted MRI influences the classification of brain microbleeds","volume":"65","author":"Gregoire","year":"2010","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0071","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.tjpad.2025.100094_bib0072","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","article-title":"Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease","volume":"82","author":"Salloway","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100094_bib0074","unstructured":"ARIA Insights From Donanemab Trials. Steven M. Greenberg, Paul Ardayfio, Chakib Battioui, Jennifer A. Zimmer, Cynthia D. Evans, Hong Wang, Emel Serap Monkul, Ming Lu, JonDavid Sparks, Scott Andersen, Emily C. Collins, Dawn A. Brooks, John R. Sims. Clinical Trials on Alzheimer's Disease (CTAD) \u201316th Annual Conference Boston, Massachusetts, USA, and online, October 24 - 27, 2023."},{"key":"10.1016\/j.tjpad.2025.100094_bib0075","unstructured":"https:\/\/www.alzforum.org\/news\/conference-coverage\/trontinemab-data-strengthen-hope-brain-shuttles."},{"issue":"23","key":"10.1016\/j.tjpad.2025.100094_bib0076","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1212\/WNL.0000000000004704","article-title":"Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.tjpad.2025.100094_bib0079","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181dad605","article-title":"Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy","volume":"74","author":"Linn","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100094_bib109","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/STROKEAHA.122.042407","article-title":"Comparison of Boston Criteria v2.0\/v1.5 for Cerebral Amyloid Angiopathy to Predict Recurrent Intracerebral Hemorrhage","volume":"54","author":"Fandler-H\u00f6fler","year":"2023","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100094_bib0077","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0078","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/alz.12366","article-title":"Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis","volume":"18","author":"J\u00e4kel","year":"2022","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1016\/j.tjpad.2025.100094_bib117","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","article-title":"The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study","volume":"21","author":"Charidimou","year":"2022","journal-title":"Lancet Neurol"},{"issue":"20","key":"10.1016\/j.tjpad.2025.100094_bib0083","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of Gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100094_bib0084","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.hlc.2016.03.016","article-title":"Efficacy and safety of percutaneous left atrial appendage occlusion for stroke prevention in nonvalvular atrial fibrillation: a meta-analysis of contemporary studies","volume":"25","author":"Xu","year":"2016","journal-title":"Heart Lung Circ"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0086","first-page":"e12101","article-title":"Symptomatic amyloid-related imaging abnormalities in an APOE \u03b54\/\u03b54 patient treated with aducanumab","volume":"12","author":"VandeVrede","year":"2020","journal-title":"Alzheimers Dement Amst Neth"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0088","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-Amyloid-targeting antibodies: a systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0899-7071(03)00191-8","article-title":"CNS vasculitis and vasculopathy: efficacy and usefulness of diffusion-weighted echoplanar MR imaging","volume":"28","author":"Moritani","year":"2004","journal-title":"Clin Imaging"},{"key":"10.1016\/j.tjpad.2025.100094_bib0091","article-title":"Amyloid beta-related angiitis presenting as multiple cerebral infarcts","volume":"3","author":"Mehta","year":"2023","journal-title":"Neuroimmunol Rep"},{"key":"10.1016\/j.tjpad.2025.100094_bib0092","doi-asserted-by":"crossref","first-page":"8192","DOI":"10.1002\/alz.14223","article-title":"Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab","volume":"20","author":"Gibson","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100094_bib0093","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3174\/ajnr.A7586","article-title":"Amyloid-related imaging abnormalities with emerging Alzheimer Disease therapeutics: detection and reporting recommendations for clinical practice","volume":"43","author":"Cogswell","year":"2022","journal-title":"AJNR Am J Neuroradiol"},{"issue":"20","key":"10.1016\/j.tjpad.2025.100094_bib0094","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: a systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100094_bib0095","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2015.4078","article-title":"Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation","volume":"73","author":"Auriel","year":"2016","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100094_bib0096","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaneurol.2020.1782","article-title":"Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation","volume":"77","author":"Regenhardt","year":"2020","journal-title":"JAMA Neurol"},{"issue":"18","key":"10.1016\/j.tjpad.2025.100094_bib0097","doi-asserted-by":"crossref","first-page":"e1809","DOI":"10.1212\/WNL.0000000000012778","article-title":"Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation: a multicenter prospective longitudinal cohort study","volume":"97","author":"Antolini","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100094_bib0098","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer's disease","volume":"13","author":"Withington","year":"2022","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib118","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.drudis.2021.11.020","article-title":"Update on treatment strategies for vasculitis affecting the central nervous system","volume":"27","author":"Hecker","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.tjpad.2025.100094_bib0099","unstructured":"US FDA OKs monthly maintenance dosing for Eisai\/Biogen\u2019s Alzheimer\u2019s drug | Reuters n.d. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/us-fda-oks-monthly-maintenance-dosing-eisaibiogens-alzheimers-drug-2025-01-26\/ (accessed February 21, 2025)."},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0100","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ijms21030952","article-title":"Protofibrils of amyloid-\u03b2 are important targets of a disease-modifying approach for Alzheimer's disease","volume":"21","author":"Ono","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100094_bib0101","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer's disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100094_bib0102","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100094_bib0103","unstructured":"Alzheimer Therapeutic Program | Brigham and Women's Hospital [Internet]. [cited 2025 Jan 6]. Available from: https:\/\/www.brighamandwomens.org\/neurology\/cognitive-and-behavioral-neurology\/alzheimer-therapeutic-program."},{"issue":"3","key":"10.1016\/j.tjpad.2025.100094_bib0104","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Agin Health"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100094_bib0105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12325-021-01999-x","article-title":"The role of Cetirizine in the changing landscape of IV antihistamines: a narrative review","volume":"39","author":"Blaiss","year":"2022","journal-title":"Adv Ther"},{"issue":"Supplement_7","key":"10.1016\/j.tjpad.2025.100094_bib0106","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology"},{"issue":"13","key":"10.1016\/j.tjpad.2025.100094_bib0107","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jama.2024.2991","article-title":"Use of Lecanemab for patients with cardiovascular disease: the challenge of uncertainty","volume":"331","author":"Ko","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100094_bib0108","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/jcm13051245","article-title":"The impact of anti-amyloid immunotherapies on stroke care","volume":"13","author":"Bilodeau","year":"2024","journal-title":"J Clin Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072500038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072500038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:16:09Z","timestamp":1744517769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S227458072500038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S227458072500038X"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100094","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100094"}}